Cutting-edge science for animal health
We developed a highly advanced antibody discovery platform for cats.
Kedi’s discovery platform combines experimental and computational biology to enable a new era in veterinary therapies.
Our technology facilitates the discovery and development of antibody and peptide therapies that match the feline immune system. Kedi’s approach is fast, cost-effective and scalable to other species without any animal experiments.
The core of Kedi’s platform is highly diverse, fully feline phage display libraries. These allow the discovery of species-specific antibody therapies for cats, replacing the traditional path of rodent immunisation with a more humane alternative.
Our internal drug discovery campaigns showed industry-leading hit rates, yielding a high number of potent antibody candidates. We established an experimental setup to further characterise these candidates and validate their function in the lab.
Unique genetic insights into animals empower new therapies
We use molecular biology tools to analyse ethically obtained samples from healthy and diseased cats. The results help build a proprietary database of feline health, which is used to optimize our drug candidates.
Guided by these molecular and clinical data, Kedi Bioscience is developing half-life extended therapeutics that require less frequent administrations.
Veterinary drug development in the age of AI
We combine our unique data with public resources and fine-tune antibody AI models, specifically for veterinary therapeutics. Our computational complementation of drug development decreases the intensity of required lab work.
Kedi Bioscience operates 3 models aimed at (i) enhancing therapeutic effects, (ii) mitigating risk of immunogenicity, and (iii) enhancing the manufacturing yield of our drug candidates. These in silico additions to our technology allow us to screen candidates rapidly and engineer therapeutics with low clinical safety risk and high manufacturability.
Our state-of-the-art veterinary drug discovery technology doesn’t require any animal experiments.
Kedi doesn’t conduct any pre-clinical experiments in animals. Instead, we combine the existing knowledge from human drug research with ethically obtained, proprietary animal data.
We believe that science can and should minimise the suffering endured by animals and humans during drug development.
Each of our R&D programs is based on a careful consideration of numerous similarities and discrepancies amongst many species. We evaluate protein structures, disease pathways, genomics, and clinical patient findings to accelerate drug development.
We generate unique scientific insights into animal biology and hope to reduce overall animal experimentation, contributing to ethical development of new medicines for all species.
A collaborative approach to deliver new medicines fast
Most of our experimental work takes place in the external laboratories of trusted contract research organisations based in Europe. This helps us stay lean and build on existing, specialised labs with experienced workforce.
We are always looking to partner with innovative companies who push the boundaries of healthcare and technology for both humans and animals.
